Karyopharm Therapeutics Inc. (KPTI) DCF Valuation
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Karyopharm Therapeutics Inc. (KPTI) Bundle
Optimize your efficiency and improve precision with our (KPTI) DCF Calculator! Utilizing real data from Karyopharm Therapeutics Inc. and customizable assumptions, this tool empowers you to forecast, analyze, and value (KPTI) just like an experienced investor.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 40.9 | 108.1 | 209.8 | 157.1 | 146.0 | 205.2 | 288.2 | 404.9 | 568.9 | 799.2 |
| Revenue Growth, % | 0 | 164.31 | 94.12 | -25.14 | -7.03 | 40.49 | 40.49 | 40.49 | 40.49 | 40.49 |
| EBITDA | -182.9 | -167.9 | -97.0 | -139.3 | -118.4 | -170.7 | -239.8 | -336.9 | -473.3 | -665.0 |
| EBITDA, % | -447.34 | -155.3 | -46.22 | -88.69 | -81.09 | -83.2 | -83.2 | -83.2 | -83.2 | -83.2 |
| Depreciation | 1.0 | 1.0 | .8 | .6 | .5 | 1.8 | 2.5 | 3.6 | 5.0 | 7.1 |
| Depreciation, % | 2.38 | 0.89929 | 0.37604 | 0.39536 | 0.36293 | 0.88309 | 0.88309 | 0.88309 | 0.88309 | 0.88309 |
| EBIT | -183.9 | -168.8 | -97.8 | -139.9 | -119.0 | -171.2 | -240.5 | -337.8 | -474.6 | -666.8 |
| EBIT, % | -449.72 | -156.2 | -46.6 | -89.08 | -81.46 | -83.43 | -83.43 | -83.43 | -83.43 | -83.43 |
| Total Cash | 264.0 | 273.5 | 228.6 | 278.0 | 191.4 | 205.2 | 288.2 | 404.9 | 568.9 | 799.2 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 7.9 | 12.9 | 22.5 | 47.1 | 27.0 | 37.1 | 52.1 | 73.1 | 102.7 | 144.3 |
| Account Receivables, % | 19.23 | 11.92 | 10.72 | 29.98 | 18.46 | 18.06 | 18.06 | 18.06 | 18.06 | 18.06 |
| Inventories | .3 | 2.6 | 4.1 | 4.2 | 3.0 | 4.1 | 5.8 | 8.1 | 11.4 | 16.0 |
| Inventories, % | 0.84611 | 2.45 | 1.96 | 2.69 | 2.08 | 2 | 2 | 2 | 2 | 2 |
| Accounts Payable | 1.0 | 4.5 | 1.6 | 2.8 | 3.1 | 4.6 | 6.5 | 9.1 | 12.7 | 17.9 |
| Accounts Payable, % | 2.41 | 4.12 | 0.76399 | 1.77 | 2.14 | 2.24 | 2.24 | 2.24 | 2.24 | 2.24 |
| Capital Expenditure | -.2 | -.1 | -5.7 | -.1 | .0 | -1.4 | -2.0 | -2.8 | -3.9 | -5.5 |
| Capital Expenditure, % | -0.50375 | -0.13415 | -2.72 | -0.07512383 | 0 | -0.68708 | -0.68708 | -0.68708 | -0.68708 | -0.68708 |
| Tax Rate, % | -0.22623 | -0.22623 | -0.22623 | -0.22623 | -0.22623 | -0.22623 | -0.22623 | -0.22623 | -0.22623 | -0.22623 |
| EBITAT | -183.9 | -169.1 | -98.0 | -140.2 | -119.2 | -171.2 | -240.5 | -337.8 | -474.6 | -666.8 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -190.4 | -172.1 | -116.8 | -163.3 | -97.0 | -180.4 | -254.7 | -357.8 | -502.7 | -706.3 |
| WACC, % | 10.95 | 10.95 | 10.95 | 10.95 | 10.95 | 10.95 | 10.95 | 10.95 | 10.95 | 10.95 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1,383.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -720 | |||||||||
| Terminal Value | -8,052 | |||||||||
| Present Terminal Value | -4,790 | |||||||||
| Enterprise Value | -6,174 | |||||||||
| Net Debt | 125 | |||||||||
| Equity Value | -6,298 | |||||||||
| Diluted Shares Outstanding, MM | 114 | |||||||||
| Equity Value Per Share | -55.14 |
What You Will Get
- Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to develop various scenarios.
- Real-World Data: Karyopharm Therapeutics Inc.'s (KPTI) financial data pre-filled to accelerate your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value for you.
- Customizable and Professional: A sleek Excel model that adjusts to your valuation requirements.
- Built for Analysts and Investors: Perfect for testing projections, validating strategies, and enhancing efficiency.
Key Features
- Customizable Financial Inputs: Adjust essential metrics such as revenue growth, EBITDA %, and capital investments.
- Instant DCF Valuation: Quickly computes intrinsic value, NPV, and additional financial metrics.
- High-Precision Accuracy: Leverages Karyopharm’s actual financial data for credible valuation results.
- Streamlined Scenario Analysis: Effortlessly evaluate various assumptions and analyze different outcomes.
- Efficiency Booster: Remove the complexity of creating intricate valuation models from the ground up.
How It Works
- 1. Access the Template: Download and open the Excel file featuring Karyopharm Therapeutics Inc. (KPTI) preloaded data.
- 2. Modify Assumptions: Adjust key parameters such as growth rates, WACC, and capital expenditures.
- 3. See Results Instantly: The DCF model automatically computes intrinsic value and NPV.
- 4. Explore Scenarios: Evaluate multiple forecasts to assess various valuation outcomes.
- 5. Present with Assurance: Deliver professional valuation insights to back your strategic decisions.
Why Choose Karyopharm Therapeutics Inc. (KPTI)?
- Innovative Treatments: Pioneering therapies targeting cancer and other serious diseases.
- Robust Pipeline: A diverse portfolio of drug candidates in various stages of development.
- Expert Leadership: A team of seasoned professionals with extensive industry experience.
- Commitment to Research: Ongoing investment in research and development to advance healthcare solutions.
- Strong Partnerships: Collaborations with leading organizations enhance our capabilities and reach.
Who Should Use This Product?
- Professional Investors: Develop comprehensive and trustworthy valuation models for analyzing Karyopharm Therapeutics Inc. (KPTI) in their portfolios.
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions regarding Karyopharm Therapeutics Inc. (KPTI).
- Consultants and Advisors: Offer clients precise valuation insights related to Karyopharm Therapeutics Inc. (KPTI) stock.
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling with Karyopharm Therapeutics Inc. (KPTI).
- Biotech Enthusiasts: Gain insights into how biotech firms like Karyopharm Therapeutics Inc. (KPTI) are valued in the financial markets.
What the Template Contains
- Preloaded KPTI Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.